Addex amends at-the-market offering agreement with H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
December 11, 2025 1:00 AM ESTAd Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the ATM Agreement) with H.C. Wainwright & Co., LLC (H.C. Wainwright & Co.) initially entered into on January 30, 2024. The at-the-market offering program enables Addex to offer and sell, from time to time at its sole... More
